Short answer
Abbott Laboratories (ABT) filed its Q3 2025 10-Q quarterly report on Oct 29, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $11.4B (up 6.9% year over year) with net income of $1.6B.
Q3 2025 key financials · XBRL
- Revenue
- $11.4B
- +6.9% YoY · +2.0% QoQ
- Net income
- $1.6B
- −0.1% YoY · −7.6% QoQ
- Operating margin
- 18.1%
- EPS (diluted)
- $0.93
- −1.1% YoY · −7.9% QoQ
Source: XBRL data from the Abbott Laboratories (ABT) Q3 2025 10-Q on SEC EDGAR. USD.
Abbott Laboratories Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $11.37B Q3 2025, up 6.9% YoY vs $10.64B Q3 2024, excluding FX impact increase 5.5%
- Gross margin 51.7% Q3 2025 vs 51.4% Q3 2024, Nine months margin 52.4% vs 51.0% YoY
- Best segment growth: Medical Devices +14.8% Q3, Diabetes Care up 18.7%, worst: Diagnostic Products sales down 6.6% Q3 (excl. COVID-19 test sales)
- Cash from operating activities $6.3B first nine months 2025, up $561M YoY, Cash down slightly from $7.6B to $7.5B due to debt repayments $1.5B
- Management notes ongoing COVID-19 testing decline, foreign exchange impacts, regulatory approvals for new devices, tax disputes with IRS, expects to maintain investment grade rating
Risk Factors
- Section 'risk_factors' was empty or not found.
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Abbott Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.